全文获取类型
收费全文 | 6534篇 |
免费 | 554篇 |
国内免费 | 12篇 |
专业分类
耳鼻咽喉 | 73篇 |
儿科学 | 270篇 |
妇产科学 | 149篇 |
基础医学 | 720篇 |
口腔科学 | 139篇 |
临床医学 | 740篇 |
内科学 | 1154篇 |
皮肤病学 | 77篇 |
神经病学 | 641篇 |
特种医学 | 187篇 |
外科学 | 954篇 |
综合类 | 138篇 |
一般理论 | 2篇 |
预防医学 | 855篇 |
眼科学 | 177篇 |
药学 | 369篇 |
中国医学 | 6篇 |
肿瘤学 | 449篇 |
出版年
2023年 | 62篇 |
2022年 | 99篇 |
2021年 | 235篇 |
2020年 | 102篇 |
2019年 | 173篇 |
2018年 | 201篇 |
2017年 | 146篇 |
2016年 | 132篇 |
2015年 | 166篇 |
2014年 | 200篇 |
2013年 | 274篇 |
2012年 | 347篇 |
2011年 | 364篇 |
2010年 | 159篇 |
2009年 | 170篇 |
2008年 | 302篇 |
2007年 | 289篇 |
2006年 | 237篇 |
2005年 | 268篇 |
2004年 | 252篇 |
2003年 | 231篇 |
2002年 | 199篇 |
2001年 | 168篇 |
2000年 | 197篇 |
1999年 | 139篇 |
1998年 | 68篇 |
1997年 | 47篇 |
1996年 | 64篇 |
1995年 | 44篇 |
1994年 | 57篇 |
1993年 | 46篇 |
1992年 | 101篇 |
1991年 | 105篇 |
1990年 | 101篇 |
1989年 | 97篇 |
1988年 | 91篇 |
1987年 | 80篇 |
1986年 | 88篇 |
1985年 | 71篇 |
1984年 | 62篇 |
1983年 | 64篇 |
1982年 | 53篇 |
1981年 | 37篇 |
1980年 | 38篇 |
1979年 | 65篇 |
1978年 | 59篇 |
1974年 | 39篇 |
1973年 | 39篇 |
1970年 | 45篇 |
1969年 | 39篇 |
排序方式: 共有7100条查询结果,搜索用时 15 毫秒
61.
62.
63.
Austin E. Doyle 《Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy》1990,4(1):13-18
Summary There is very suggestive evidence for a role of serotonin release from platelets in the mechanisms for platelet aggregation, arterial thrombosis, and arterial spasm. These effects are mediated via the 5HT2 receptor and are specifically antagonized by ketanserin. The recently published PACK study was a randomized controlled trial of the effects of ketanserin in patients with intermittent claudication. The purpose of the trial was to discover whether ketanserin treatment would reduce the incidence of atherosclerotic complications such as myocardial infarction or stroke. An unexpected adverse interaction between ketanserin and potassium-losing diuretics was observed, causing an excess of deaths in the group taking this combination of drugs. The intention-to-treat analysis showed no overall difference between ketanserin and placebo in terms of cardiovascular complications. Withdrawal of patients taking potassium-losing diuretics left insufficient numbers of patients in the study to answer the original question. However, the on-treatment analysis excluding those taking the combination suggested strongly, although did not prove, that ketanserin reduced thrombotic episodes by about 25%. It is concluded that the risks of interactions between many drugs and potassium-losing diuretics make the use of the latter undesirable. Further studies on ketanserin, possibly combined with thromboxane A2 inhibitors, seem highly desirable. 相似文献
64.
65.
66.
67.
68.
69.
H J Meadows M H Harries M Thompson C D Benham 《British journal of pharmacology》1997,121(7):1334-1338
- 4-Amino-7-hydroxy-2-methyl-5,6,7,8,-tetrahydrobenzo[b]thieno[2,3-b]pyridine-3-carboxylic acid, but-2-ynyl ester (SB-205384) and other γ-aminobutyric acidA (GABAA) receptor modulators were tested for their effects on GABA-activated chloride currents in rat cerebellar granule cells by use of the whole-cell patch clamp technique.
- The major effect of SB-205384 on GABAA-activated current was an increase in the half-life of decay of the response once the agonist had been removed. This is in contrast to many GABAA receptor modulators that have previously been shown to potentiate GABA-activated currents.
- This profile could be explained if SB-205384 stabilizes the channel in open and desensitized states so that channel closing is dramatically slowed. Such a modulatory profile may produce a novel behavioural profile in vivo.
70.
Age as a prognostic factor in the malignant melanoma population 总被引:3,自引:0,他引:3
Paul F. Austin MD C. Wayne Cruse MD Gary Lyman MD MPH Kenneth Schroer MD Frank Glass MD Dr. Douglas S. Reintgen MD 《Annals of surgical oncology》1994,1(6):487-494
Background: The incidence of malignant melanoma is increasing faster than any other cancer, and the state of Florida has one of the highest incidence of melanoma in the United States. This increased incidence is thought to be due to the intense sunlight exposure and ultraviolet radiation exposure in the elderly population. With the increased emphasis on issues of aging, it is appropriate to study the role of age as a prognostic factor for malignant melanoma in the Florida population.
Methods: A retrospective, computer-aided search identified 442 consecutively registered patients with malignant melanoma at the Cutaneous Oncology Program. All patients had stage 1 or 2 disease (cutaneous disease only) at diagnosis. Prognostic variables analyzed included the most powerful factors for stage 1 and 2 melanoma, tumor thickness, ulceration, and Clark level of invasion. Other prognostic variables included in the analysis were the clinical variables of sex and primary site (axial vs. extremity). The population was divided into patients 65 and >65 years of age.
Results: Significant disease-free survival differences were encountered in the older population, with only 55% of the elderly population being disease free at 5 years compared with 65% for the younger population (p=0.0073). However, a greater percentage of patients with melanoma who were >65 years of age had ulcerated lesions (17.5% vs. 12.9%) and a greater percentage of thick lesions at diagnosis (67.2% vs. 62.7%). Both of these prognostic factors would bias the older population with a poorer survival. A stepwise regression analysis of the entire population was performed, treating age as a continuous variable. Surprisingly, increasing age along with tumor thickness were the only significant predictors for disease-free survival. After inclusion of these two prognostic variables, none of the other prognostic factors, including Clark level, ulceration, sex, and primary site, added to the prognostic model.
Conclusions: From this analysis, it is apparent that geriatric patients with melanoma have a worse prognosis than a younger control population, even after the correction for the more commonly cited prognostic factors. This information should be used in mathematical modeling to identify high-risk populations who are candidates for perhaps more aggressive primary or adjuvant therapies.Presented at the 46th Annual Cancer Symposium of The Society of Surgical Oncology, Los Angeles, California, March 18–21, 1993. 相似文献